Good Predictions: FDA Encouraged by Biomarker Progress
This article was originally published in RPM Report
Executive Summary
It's been just over a year since the Food & Drug Administration started down the Critical Path to drug development reform, and senior agency staffers are already exuding confidence that at least one of its first showcase projects will be a winner.